Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...

Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week ...

Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from ...

Cantor Fitzgerald upgraded shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a neutral rating to an overweight rating in a research note published on Wednesday morning, Marketbeat reports.

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

In the preceding three months, 4 analysts have released ratings for Beam Therapeutics (NASDAQ:BEAM), presenting a wide array of perspectives from bullish to bearish. The following table summarizes ...

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that ...

Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. As of January 29, 2025, the average one-year ...

Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...

Beam Therapeutics (BEAM – Research Report) received a Buy rating and a $37.00 price target from Bernstein analyst William Pickering today. The ...